Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the appointment of Barry A. Labinger to its Board of Directors. Mr. Labinger is Executive Vice President and Chief Commercial Officer of Human Genome Sciences. "We are very pleased to have Barry join our Board," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Anadys. "His impressive commercial credentials and product marketing savvy enhance our Board's collective expertise." Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, added, "Our product candidates, ANA598 and ANA773, are advancing toward a future HCV treatment landscape based on combination regimens. Barry's perspective will be invaluable as we optimize our development plans to reflect commercial utility as part of these combination regimens." Mr. Labinger has served as Executive Vice President and Chief Commercial Officer of Human Genome Sciences since August 2005. Mr. Labinger has more than 20 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Prior to joining Human Genome Sciences, Mr. Labinger served as Division Vice President of 3M Pharmaceuticals, a global division of 3M Company, with marketed products in dermatology, women's health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University. "I am delighted to join the Anadys Board of Directors," said Mr. Labinger. "Anadys is a thriving biopharmaceutical company developing two promising clinical-stage assets in a very dynamic therapeutic space. This is an exciting opportunity for me and I look forward to being a part of Anadys during this pivotal stage of its development."